This podcast discusses the ISCT annual meeting, focusing on the potential replacement of autologous cell therapy with allogeneic cell therapy and the role of exosomes in replacing mesenchymal stromal cells. They also explore the differences between autologous and allogeneic cell therapies, the use of AI and machine learning in cell and gene therapy, innovative platforms and products in the field, and the use of axosomes in mesenchymal stem cell therapy.
01:09:01
AI Summary
AI Chapters
Episode notes
auto_awesome
Podcast summary created with Snipd AI
Quick takeaways
Different approaches of allogenic and autologous cell therapies have distinct advantages and limitations, including immune rejection and manufacturing scalability.
Exosomes and mesenchymal stem cells (MSCs) show great potential in cell therapy, particularly in targeted drug delivery and immunomodulation.
Exosomes can be utilized for personalized medicine, delivering therapeutic payloads to specific cells and tissues with the help of AI and machine learning technologies.
Deep dives
The potential of allogeneic and autologous cell therapies
The podcast episode explores the potential of allogeneic and autologous cell therapies. The CEO of Orgenesis discusses the differences between these two approaches. Autologous therapy involves using a patient's own cells to create a therapeutic product, while allogeneic therapy uses cells taken from another patient. These therapies have different advantages and limitations, such as immune rejection and manufacturing scalability. The CEO emphasizes the importance of reprogramming cells for personalized medicine and highlights the need for standardized systems in cell therapy manufacturing. The cost of production is expected to decrease as the industry matures and adopts more automated and standardized processes.
The evolving field of exosomes and MSCs
The CEO of Cell Prothera discusses the evolution of exosomes and mesenchymal stem cells (MSCs) in cell therapy. Exosomes are small vesicles secreted by cells, and they have potential applications in targeted drug delivery and immunomodulation. The CEO highlights the advantages of cell-free therapies like exosomes, which avoid issues such as immune rejection and unwanted differentiation. MSCs can be cultured using advanced technologies like hollow fiber bioreactors, which allow for scalable production. The CEO explains the importance of optimizing cell culture conditions and process control for consistent and high-quality exosome production. The field of exosomes and MSCs is expected to continue advancing, offering new possibilities for cell-based therapies.
The role of exosomes in cell therapy and disease treatment
The conversation with the director of scientific affairs at Terumo Blood and Cell Technologies focuses on the use of exosomes in cell therapy and disease treatment. Exosomes, small vesicles secreted by cells, can carry specific molecules and be targeted to certain cell types. This makes them valuable for delivering therapeutic payloads to specific cells and tissues. Terumo provides technologies for exosome production and culturing mesenchymal stem cells (MSCs). They emphasize the potential of exosomes in personalized medicine and highlight the advantages of cell-free therapies over cellular-based treatments. The director also discusses the role of AI and machine learning in improving process control and decision-making in cell manufacturing.
Utilizing axosomes for innovative treatments
The CSO of Biosenic discusses the potential of axosomes for innovative treatments. Axosomes are small vesicles secreted by cells, and they can be loaded with therapeutic molecules. Biosenic aims to combine their ALLOB cell therapy platform, derived from bone marrow mesenchymal stem cells, with arsenic trioxide for creating axosomes. The goal is to develop targeted treatments for autoimmune diseases such as lupus, psoriasis, cystinobronchitis, and multiple sclerosis. Axosomes offer benefits such as targeted delivery of treatment, standardization, and cost-effectiveness. Biosenic is actively exploring partnerships and technologies to create and load axosomes, with the aim of advancing to preclinical trials and beyond.
Challenges and future prospects in axosome development
Developing axosomes for innovative treatments poses technical challenges. Finding the right partners and technologies for axosome production and loading is crucial. Biosenic is actively seeking collaborations with companies in Belgium. Multiple technologies will be evaluated to determine the best approach. Technical difficulties arise in creating and qualifying axosomes, as well as choosing the optimal loading methods. Despite these challenges, axosomes offer promising prospects in the field of personalized medicine and targeted therapies for various diseases. Biosenic aims to overcome these obstacles and move towards preclinical trials in the coming years.
The International Society for Cell & Gene Therapy (ISCT), the global society of more than 3,000 members dedicated to the translation of cell and gene therapies (CGT) into safe and effective treatments to improve patient lives, recently hosted the largest translation-focused event connecting academic, regulatory and industry experts from around the world to collaborate and find tangible solutions to the most critical issues affecting the development of advanced therapies.
The event took place in Paris, France.
The ISCT 2023 Translational Pathway Program featured plenary and concurrent sessions designed to address and overcome barriers at each stage of development across a full range of modalities such as CAR T, iPSC, and a dedicated half-day program on unlocking the potential of exosomes (EVs).
In this week’s podcast, we look into two of the sessions: ‘Will allogeneic cell therapy replace autologous when it comes down to patient access?’ and ‘Have exosomes replaced MSCs?’
Our guests to talk about these subjects are Carole Nicco, CSO at BioSenic; Dalip Sethi, director of scientific affairs, Terumo Blood and Cell Technologies; Matthieu de Kalbermatten, CEO of CellProthera; and Vered Caplan, CEO of Orgenesis.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
